Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer
Pancreatic cancer has an exclusive inhibitory tumor microenvironment characterized by a dense mechanical barrier, profound infiltration of immunosuppressive cells, and a lack of penetration of effector T cells, which constitute an important cause for recurrence and metastasis, resistance to chemothe...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.956984/full |
| _version_ | 1798001284352049152 |
|---|---|
| author | Huiru Zhang Huiru Zhang Huiru Zhang Huiru Zhang Longyun Ye Longyun Ye Longyun Ye Longyun Ye Xianjun Yu Xianjun Yu Xianjun Yu Xianjun Yu Kaizhou Jin Kaizhou Jin Kaizhou Jin Kaizhou Jin Weiding Wu Weiding Wu Weiding Wu Weiding Wu |
| author_facet | Huiru Zhang Huiru Zhang Huiru Zhang Huiru Zhang Longyun Ye Longyun Ye Longyun Ye Longyun Ye Xianjun Yu Xianjun Yu Xianjun Yu Xianjun Yu Kaizhou Jin Kaizhou Jin Kaizhou Jin Kaizhou Jin Weiding Wu Weiding Wu Weiding Wu Weiding Wu |
| author_sort | Huiru Zhang |
| collection | DOAJ |
| description | Pancreatic cancer has an exclusive inhibitory tumor microenvironment characterized by a dense mechanical barrier, profound infiltration of immunosuppressive cells, and a lack of penetration of effector T cells, which constitute an important cause for recurrence and metastasis, resistance to chemotherapy, and insensitivity to immunotherapy. Neoadjuvant therapy has been widely used in clinical practice due to its many benefits, including the ability to improve the R0 resection rate, eliminate tumor cell micrometastases, and identify highly malignant tumors that may not benefit from surgery. In this review, we summarize multiple aspects of the effect of neoadjuvant therapy on the immune microenvironment of pancreatic cancer, discuss possible mechanisms by which these changes occur, and generalize the theoretical basis of neoadjuvant chemoradiotherapy combined with immunotherapy, providing support for the development of more effective combination therapeutic strategies to induce potent immune responses to tumors. |
| first_indexed | 2024-04-11T11:34:58Z |
| format | Article |
| id | doaj.art-a974b5823063411a86e9c2da995ff961 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T11:34:58Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a974b5823063411a86e9c2da995ff9612022-12-22T04:26:01ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.956984956984Neoadjuvant therapy alters the immune microenvironment in pancreatic cancerHuiru Zhang0Huiru Zhang1Huiru Zhang2Huiru Zhang3Longyun Ye4Longyun Ye5Longyun Ye6Longyun Ye7Xianjun Yu8Xianjun Yu9Xianjun Yu10Xianjun Yu11Kaizhou Jin12Kaizhou Jin13Kaizhou Jin14Kaizhou Jin15Weiding Wu16Weiding Wu17Weiding Wu18Weiding Wu19Department of Pancreatic Surgery, Shanghai Cancer Centre, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaShanghai Pancreatic Cancer Institute, Fudan University, Shanghai, ChinaPancreatic Cancer Institute, Fudan University, Shanghai, ChinaDepartment of Pancreatic Surgery, Shanghai Cancer Centre, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaShanghai Pancreatic Cancer Institute, Fudan University, Shanghai, ChinaPancreatic Cancer Institute, Fudan University, Shanghai, ChinaDepartment of Pancreatic Surgery, Shanghai Cancer Centre, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaShanghai Pancreatic Cancer Institute, Fudan University, Shanghai, ChinaPancreatic Cancer Institute, Fudan University, Shanghai, ChinaDepartment of Pancreatic Surgery, Shanghai Cancer Centre, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaShanghai Pancreatic Cancer Institute, Fudan University, Shanghai, ChinaPancreatic Cancer Institute, Fudan University, Shanghai, ChinaDepartment of Pancreatic Surgery, Shanghai Cancer Centre, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaShanghai Pancreatic Cancer Institute, Fudan University, Shanghai, ChinaPancreatic Cancer Institute, Fudan University, Shanghai, ChinaPancreatic cancer has an exclusive inhibitory tumor microenvironment characterized by a dense mechanical barrier, profound infiltration of immunosuppressive cells, and a lack of penetration of effector T cells, which constitute an important cause for recurrence and metastasis, resistance to chemotherapy, and insensitivity to immunotherapy. Neoadjuvant therapy has been widely used in clinical practice due to its many benefits, including the ability to improve the R0 resection rate, eliminate tumor cell micrometastases, and identify highly malignant tumors that may not benefit from surgery. In this review, we summarize multiple aspects of the effect of neoadjuvant therapy on the immune microenvironment of pancreatic cancer, discuss possible mechanisms by which these changes occur, and generalize the theoretical basis of neoadjuvant chemoradiotherapy combined with immunotherapy, providing support for the development of more effective combination therapeutic strategies to induce potent immune responses to tumors.https://www.frontiersin.org/articles/10.3389/fimmu.2022.956984/fullpancreatic cancertumor environment (TME)immuneimmunologyneoadjuvant therapy |
| spellingShingle | Huiru Zhang Huiru Zhang Huiru Zhang Huiru Zhang Longyun Ye Longyun Ye Longyun Ye Longyun Ye Xianjun Yu Xianjun Yu Xianjun Yu Xianjun Yu Kaizhou Jin Kaizhou Jin Kaizhou Jin Kaizhou Jin Weiding Wu Weiding Wu Weiding Wu Weiding Wu Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer Frontiers in Immunology pancreatic cancer tumor environment (TME) immune immunology neoadjuvant therapy |
| title | Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer |
| title_full | Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer |
| title_fullStr | Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer |
| title_full_unstemmed | Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer |
| title_short | Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer |
| title_sort | neoadjuvant therapy alters the immune microenvironment in pancreatic cancer |
| topic | pancreatic cancer tumor environment (TME) immune immunology neoadjuvant therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.956984/full |
| work_keys_str_mv | AT huiruzhang neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT huiruzhang neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT huiruzhang neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT huiruzhang neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT longyunye neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT longyunye neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT longyunye neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT longyunye neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT xianjunyu neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT xianjunyu neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT xianjunyu neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT xianjunyu neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT kaizhoujin neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT kaizhoujin neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT kaizhoujin neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT kaizhoujin neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT weidingwu neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT weidingwu neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT weidingwu neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer AT weidingwu neoadjuvanttherapyalterstheimmunemicroenvironmentinpancreaticcancer |